Clinical Trial: Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjogren's Disease With High Symptom Burden

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07621809) titled 'Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjogren's Disease With High Symptom Burden' on May 26.

Brief Summary: The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjogren's disease who have high symptom burden.

Study Start Date: July 15

Study Type: INTERVENTIONAL

Condition: Sjogren's Disease

Intervention: DRUG: VAY736

VAY736 once monthly solution for injection for subcutaneous use.

DRUG: Placebo

Placebo once monthly soluti...